Mergers & Acquisitions Mergers & Acquisitions

AstraZeneca files $39 billion acquisition of Alexion Pharmaceuticals for EU review

By Natalie McNelis
  • 01 Jun 2021 05:35
  • 01 Jun 2021 05:35
Drugmaker AstraZeneca has requested EU approval to acquire US rival Alexion Pharmaceuticals, according to an update today on the European Commission's register of deals.
The commission has set a July 5 deadline to decide on the deal.

AstraZeneca said it plans to buy Alexion for $39 billion, to establish

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Natalie McNelis

Senior Correspondent


Natalie McNelis covers mergers for MLex in Brussels. Before joining MLex in 2017, she spent 20 years as an international trade and competition lawyer in law firms including Stibbe and WilmerHale. Natalie has a BA in English from Mount Holyoke College, a JD from Harvard Law School and an LLM in EU law from KU Leuven. She is admitted to the bar in New York.

Discover MLex

Stay on top of global regulatory developments

Latest News